Study examines safety, immune response of candidate Ebola vaccines

Posted by on April 19, 2016 5:00 pm
Categories: health

A phase 1 trial has been conducted to evaluate the tolerability and immunogenicity of two candidate Ebola vaccines, an adenovirus type 26 vector vaccine (Ad26.ZEBOV), and a modified Ankara vector vaccine (MVA-BN-Filo).

Leave a Reply

Your email address will not be published. Required fields are marked *